DCOY inks private placement up to ~$21M; initial close ~ $3.5M, milestone warrants
AI Summary
Decoy Therapeutics (DCOY) announced a private placement with a healthcare-focused institutional investor that could deliver up to approximately $21 million via upfront proceeds plus milestone-tied warrant exercises. The initial closing is expected to generate about $3.5 million in gross proceeds and additional tranches hinge on regulatory/clinical milestones (EU clinical trial authorization, UK Phase 2a approval, positive human challenge data), so further dilution is conditional on those triggers. Timing: Same-day dilution is possible only if the company starts sales under the facility, and the press release does not say when that could happen.
Positives
- Initial closing expected to provide ~ $3.5M in near-term cash
- Total potential funding up to ~ $21M if milestone warrants are exercised
- Milestone-linked structure ties follow-on funding to regulatory/clinical progress
Negatives
- Milestone-based warrants create contingent future dilution if milestones are met
- No share/unit counts, warrant strike prices, or investor identity disclosed
- Timing and amount of additional funding are uncertain and contingent on future events
Filing Context
Filing and Dilution Context
Earliest dilution
Earliest dilution: after company starts sales
Dilution status
conditional
Dilution timing
Dilution status: Undetermined
Trigger type
purchase_trigger